Actively Recruiting
Dupixent and Narrowband UVB for Atopic Dermatitis
Led by Psoriasis Treatment Center of Central New Jersey · Updated on 2024-03-15
40
Participants Needed
1
Research Sites
138 weeks
Total Duration
On this page
Sponsors
P
Psoriasis Treatment Center of Central New Jersey
Lead Sponsor
R
Regeneron Pharmaceuticals
Collaborating Sponsor
AI-Summary
What this Trial Is About
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
CONDITIONS
Official Title
Dupixent and Narrowband UVB for Atopic Dermatitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female adult 18 years of age or older
- Diagnosis of moderate to severe atopic dermatitis with an EASI score of 16 or greater
- Investigator's Global Assessment (IGA) score of 3 or greater
- Body surface area (BSA) affected of 10% or greater
You will not qualify if you...
- Previous treatment with dupilumab
- Known or suspected allergy to dupilumab or its ingredients
- History of photosensitivity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Eczema Treatment Center of New Jersey
East Windsor, New Jersey, United States, 08520
Actively Recruiting
Research Team
E
Elise Nelson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here